Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

39

Revenue 2017

Orencia

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Orencia was produced by Bristol-Myers Squibb.

Opdivo drives growth at BMS, but US sales slow down

Opdivo drives growth at BMS, but US sales slow down

Overall, BMS reported fourth-quarter revenues up 22% to $5.2bn, with a solid showing from novel oral anticoagulant Eliquis (apixaban), which leaped 57% to $346m and rheumatoid arthritis therapy Orencia

Opdivo drives gain in BMS sales, but business revamp coming

Opdivo drives gain in BMS sales, but business revamp coming Away from cancer, rheumatoid arthritis treatment Orencia (abatacept) continued its buoyant run with an 18% increase to $572m, while novel oral anticoagulant Eliquis (apixaban) brought in $884m, a rise of 90%.

Shire gives up on Momenta-partnered Humira biosimilar

Shire gives up on Momenta-partnered Humira biosimilar It also has a biosimilar collaboration with generics giant Mylan covering six biologics, headed by M834, a biosimilar version of Bristol-Myers Squibb's rheumatoid arthritis drug Orencia (abatacept).

Deal Watch January 2016

Deal Watch January 2016 255. Mylan/ Momenta. Co-development, co-commercialisation . Exclusive global collaboration with Momenta for 6 biosimilars including a biosimilar version of Orencia (abatacept)  . 245. Athersys/ Healios. Licence. Development and commercialisation

Mylan buys into six biosimilars, including Orencia candidate

Mylan buys into six biosimilars, including Orencia candidate The agreement gives Mylan the rights to six biosimilars in Momenta's pipeline, including a version of Bristol-Myers Squibb's rheumatoid arthritis therapy Orencia (abatacept) which brought in sales of

1 2 3 4 5 6 7 8 9 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics